Trial Profile
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms FARAONIC
- Sponsors Bayer
- 10 Dec 2021 Status changed from active, no longer recruiting to completed.
- 08 Nov 2021 Planned End Date changed from 30 Oct 2021 to 29 Nov 2021.
- 10 Oct 2019 Status changed from recruiting to active, no longer recruiting.